JP2021533167A5 - - Google Patents

Info

Publication number
JP2021533167A5
JP2021533167A5 JP2021506506A JP2021506506A JP2021533167A5 JP 2021533167 A5 JP2021533167 A5 JP 2021533167A5 JP 2021506506 A JP2021506506 A JP 2021506506A JP 2021506506 A JP2021506506 A JP 2021506506A JP 2021533167 A5 JP2021533167 A5 JP 2021533167A5
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
seq
fusion antibody
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021506506A
Other languages
English (en)
Japanese (ja)
Other versions
JP7532338B2 (ja
JP2021533167A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/045547 external-priority patent/WO2020033577A2/en
Publication of JP2021533167A publication Critical patent/JP2021533167A/ja
Publication of JP2021533167A5 publication Critical patent/JP2021533167A5/ja
Priority to JP2024124266A priority Critical patent/JP2024153824A/ja
Application granted granted Critical
Publication of JP7532338B2 publication Critical patent/JP7532338B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506506A 2018-08-07 2019-08-07 ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物 Active JP7532338B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024124266A JP2024153824A (ja) 2018-08-07 2024-07-31 ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862715696P 2018-08-07 2018-08-07
US201862715693P 2018-08-07 2018-08-07
US201862715697P 2018-08-07 2018-08-07
US62/715,697 2018-08-07
US62/715,696 2018-08-07
US62/715,693 2018-08-07
PCT/US2019/045547 WO2020033577A2 (en) 2018-08-07 2019-08-07 Methods and compositions for increasing the activity in the cns of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024124266A Division JP2024153824A (ja) 2018-08-07 2024-07-31 ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物

Publications (3)

Publication Number Publication Date
JP2021533167A JP2021533167A (ja) 2021-12-02
JP2021533167A5 true JP2021533167A5 (enExample) 2022-08-10
JP7532338B2 JP7532338B2 (ja) 2024-08-13

Family

ID=69415150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506506A Active JP7532338B2 (ja) 2018-08-07 2019-08-07 ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物
JP2024124266A Pending JP2024153824A (ja) 2018-08-07 2024-07-31 ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024124266A Pending JP2024153824A (ja) 2018-08-07 2024-07-31 ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物

Country Status (6)

Country Link
US (1) US20240252667A1 (enExample)
EP (1) EP3833689A4 (enExample)
JP (2) JP7532338B2 (enExample)
AU (1) AU2019317460A1 (enExample)
CA (1) CA3107749A1 (enExample)
WO (1) WO2020033577A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
AU2024241509A1 (en) * 2023-03-20 2025-09-25 Spark Therapeutics, Inc. Ppt1 gene therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
CA2641070C (en) * 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
IL193282A (en) * 2006-02-06 2013-04-30 Yeda Res & Dev Chimeric protein of therapeutic enzyme and granulocyte-stimulating factor for treatment of lysosomal storage diseases
CA3184105A1 (en) * 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
JP2013507131A (ja) * 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
US8486399B2 (en) * 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
EP2910632B1 (en) * 2012-10-19 2017-07-05 Tokushima University Highly functional enzyme having modified substrate specificity of human beta-hexosaminidase b and exhibiting protease resistance
US20150023956A1 (en) * 2013-07-22 2015-01-22 Armagen Technologies, Inc. Methods and compositions for increasing enzyme activity in the cns
EP3119892B1 (en) * 2014-03-17 2021-03-10 The Hospital For Sick Children Beta-hexosaminidase protein variants and associated methods for treating gm2 gangliosdoses
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE

Similar Documents

Publication Publication Date Title
AU2009201466B2 (en) Multimeric proteins and methods of making and using same
CN112409480B (zh) 结合血清白蛋白的蛋白及其用途
EP3579875B1 (en) Anti human annexin a1 antibody
JP2020506898A5 (enExample)
JP2009523459A5 (enExample)
CN107001482A (zh) 多特异性抗体
JP2023502968A5 (enExample)
JP2016525545A5 (enExample)
JP2013515508A5 (enExample)
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
CA3118640A1 (en) Single domain antibodies that bind human serum albumin
CA3136598A1 (en) Binding molecules
US20240092905A1 (en) Dna therapeutic encoding an antibody or antigen binding fragment
RS55133B1 (sr) Antigen vezujući proteini specifični za p komponentu amiloida seruma
JP2025506341A5 (enExample)
CA3232365A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv
IL317895A (en) Anti-SARS-COV-2 antigen-binding polypeptides, polypeptide complexes and methods of using them
JP2022516660A5 (enExample)
JP2024506020A5 (enExample)
JP2025517120A5 (enExample)
US20260042865A1 (en) Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
US11028132B1 (en) Half-life optimized linker composition
WO2023039611A2 (en) Tfr antigen binding proteins and uses thereof
WO2017102835A1 (en) Binding molecule comprising an alphabody-polypeptide and an antibody
WO2018112219A4 (en) Superkine